Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Recommendation of “Hold” from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given an average recommendation of “Hold” by the seven research firms that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $4.94.

A number of equities research analysts have commented on CARM shares. BTIG Research cut shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Evercore ISI reaffirmed an “in-line” rating and issued a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. D. Boral Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Carisma Therapeutics in a research note on Monday, January 13th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Finally, Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Carisma Therapeutics Stock Performance

Shares of CARM stock opened at $0.33 on Friday. The firm has a 50 day moving average of $0.44 and a 200-day moving average of $0.67. The company has a market cap of $13.78 million, a price-to-earnings ratio of -0.21 and a beta of 1.55. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a 52 week low of $0.33 and a 52 week high of $2.30.

Institutional Investors Weigh In On Carisma Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its holdings in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Carisma Therapeutics by 11.9% during the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after purchasing an additional 24,600 shares during the last quarter. Finally, Wexford Capital LP boosted its holdings in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares during the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.